Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. Watchdog Says GSK Infringed Competition Law With “Pay-For-Delay” Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K.'s Office of Fair Trading is proceeding with its action against GlaxoSmithKline, alleging it held back generic competition to its best-selling antidepressant paroxetine from 2001 to 2004 through agreements with generic drug firms.

You may also be interested in...



Servier’s EU Nightmare Continues As Commission Moves To Shut Down Disputed IP Practices

The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.

GSK’s DoJ Settlement Requires Execs To Forfeit Bonuses If Misconduct Occurs

GlaxoSmithKline pleads guilty to promoting Paxil and Wellbutrin off-label and failing to report Avandia safety data to FDA; civil portion of settlement resolves off-label and kickback allegations involving nine products. New corporate integrity agreement gives OIG authority to require a recall.

Pipeline Watch: Phase III Starts For COVID-19 Vaccines

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel